RNA interference is a cellular mechanism that uses the gene’s DNA sequence to turn it off, a process that researchers call silencing. RNAi is triggered by double-stranded RNA (dsRNA) in a wide variety of organisms, including animals, plants, and fungi; RNAi is triggered by double-stranded RNA (dsRNA). It is widely used by researchers to silence genes to learn something about their function. Additionally, the ability to turn off the expression of a single gene makes RNAi an appealing therapeutic approach to treat genetic disorders or infectious diseases, such as those that result from the undesirable & inappropriate activity of a gene. Furthermore, RNAi is used in functional genomics and developing therapies to treat many types of cancers, viral infections, neurological disorders, and dominant disorders.
Global RNAi technology market size will grow at a significant CAGR during the forecasting period 2020–2027. The market’s growth can be attributed to its applications such as cancer treatment, treatment of viruses, parasites, bacterial diseases, maladaptive genetic mutations, control drug consumption, provide pain relief, and even modulate sleep. Additionally, in biotechnology & other fields, improving plant resistance to viral diseases resulted in novel crops such as decaffeinated coffee, nicotine-free tobacco, nutrient fortified vegetation, and hypoallergenic crops. Thus increasing applications is expected to drive the growth of the RNAi market during the forecast period. Moreover, It is a specific, potent, and highly successful technique for studying mammalian gene function and animal models and has long been a method of choice for researchers making the loss of function studies.
Furthermore, it becomes an important tool for drug discovery and biomedical research. RNAi screening is even more powerful when combined with high content imaging and data analysis techniques. The resulting multiparametric readouts provide greater insight into the understanding of gene function and their role in disease is expected to contribute to the growth of the health care industry in the forecast period.
RNAi technology has proven to be a powerful tool for researchers to silence genes to learn about their function. RNAi therapy field provides an opportunity to deliver novel drugs that could change patients’ lives, but a critical challenge is developing highly efficient pipelines for the cost-effective selection of RNAi drug candidates. Despite this, there are currently several clinical trials testing the safety and effectiveness of siRNA drugs which can be manufactured cheaply and designed to match any gene. Additionally, therapies based on RNAi are also currently being developed for viral infection, including hepatitis B and C viruses, respiratory syncytial virus, and human immunodeficiency virus. Strategies for the treatment of neurodegenerative diseases and cancers are also responsible for the growth of the global RNAi technology market in the future.
Based on the application, the global RNAi technology market is segregated into drug discovery & development, therapeutics, agriculture, and others. Moreover, therapeutics is further segment into oncology, ocular disorders, respiratory disorders, liver diseases, neurology, cardiology, ophthalmology, and metabolic disorders. The oncology segment held a higher revenue share in 2019 and is projected to dominate the RNAi technology market by 2027. It is primarily attributed to the increasing number of cancer patients in need of treatment and adoptive cell transfer therapy to cure treatment. The agricultural segment will grow with a lucrative growth rate in the forecast period. It is due to improved traits related to disease management, plant development, and crop improvement.
Based on the end-user, the global RNAi technology market is segmented into pharmaceutical & biotechnologies industries, agriculture-based industries, academic & research institutions, contract research organizations, and others. The pharmaceutical & biotechnology companies segment will dominate the global RNAi technology market by 2027. It is due to the demand for personalized medicine, increasing chronic diseases, an adaptation of reagents, and cellular research.
The agricultural segment is expected to grow significantly during the forecast period due to the invention of novel crops and crop improvement.
The global RNAi technology market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa by geography. North America is assigned a significant share by 2027 in the RNAi technology market. The growth in the region can be stated to the growing importance of advanced technology and expansion in the health care sector.
The Asia Pacific is expected to provide significant growth opportunities due to rising disease & their control and the production of animal models for research use.
Companies such as Alnylam Pharmaceuticals, Invitrogen, Benitec Biopharma Ltd, miRagen Therapeutics, Arrowhead, Filmtec Corporation, Ionis Pharmaceuticals, Quark Pharmaceuticals Inc, RXI Pharmaceuticals, Qiagen, Akcea Therapeutics, Alnylam Pharmaceuticals, Gotham Therapeutics, CureVac, BioNTech, Dicerna Pharmaceuticals, Ambion and Gradalis are the key players in the global RNAi technology market.